Acinetobacter Infections - Pipeline Insight, 2025

This “Acinetobacter Infections - Pipeline Insight, 2025” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Acinetobacter Infections pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Acinetobacter Infections: Understanding

Acinetobacter Infections: Overview

Acinetobacter is a serious gram-negative bacterial infection, with Acinetobacter baumannii accounting for 80% of cases. It can cause pneumonia, bloodstream infections, meningitis, and other suppurative infections, often in immunocompromised and hospitalized patients. Acinetobacter's resistance to many antibiotics, including carbapenems, makes it difficult to treat. Risk factors include prolonged hospital stays, antibiotic exposure, medical devices, and weakened immunity, underscoring the importance of infection control measures.

Acinetobacter infections can cause a range of symptoms depending on the site of infection. Common signs and symptoms include fever, red, swollen, warm, or painful skin areas or wounds, cough, chest pain, or trouble breathing, and burning sensations while urinating. In some cases, patients may experience headaches, sleepiness, or a stiff neck. Acinetobacter can also cause pneumonia, bloodstream infections, meningitis, urinary tract infections, and skin or wound infections, often in immunocompromised and hospitalized patients. The severity of symptoms can vary, and prompt medical attention is crucial to prevent complications and ensure effective treatment.

Acinetobacter infections, caused by opportunistic gram-negative Acinetobacter, lead to severe respiratory (e.g., hospital-acquired pneumonia) and bloodstream infections, especially dangerous for immunocompromised patients. Virulence factors like capsular polysaccharides and LPS contribute to immune evasion and septic shock. Treatment challenges arise from multidrug resistance, emphasizing the critical need for prompt, effective antibiotic therapy to enhance survival rates.

Diagnosis of Acinetobacter infections involves culturing bacteria from specimens like sputum or blood, correlating with clinical signs to confirm infection. Additional respiratory support or abnormal chest imaging in pneumonia cases aids in diagnosis.

Carbapenems, such as imipenem-cilastatin and meropenem, are the primary agents of choice for treating severe Acinetobacter infections. However, carbapenem resistance is increasingly common, necessitating the use of alternative agents like colistin, sulbactam, and tigecycline. Combination antimicrobial therapy is often used to treat multidrug-resistant Acinetobacter infections. Proper infection control measures, such as hand hygiene and environmental cleansing, are crucial in preventing the spread of Acinetobacter in healthcare settings. Prevention of Acinetobacter infections also involves judicious antimicrobial use and measures to prevent ventilator-associated pneumonia and surgical site infections.

'Acinetobacter Infections - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acinetobacter Infections pipeline landscape is provided which includes the disease overview and Acinetobacter Infections treatment guidelines. The assessment part of the report embraces, in depth Acinetobacter Infections commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acinetobacter Infections collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acinetobacter Infections R&D. The therapies under development are focused on novel approaches to treat/improve Acinetobacter Infections.

Acinetobacter Infections Emerging Drugs Chapters

This segment of the Acinetobacter Infections report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acinetobacter Infections Emerging Drugs

OMN6: Omnix Medical

OMN6 is a novel, first-in-class antimicrobial peptide (AMP) based on insect host defense peptides. Its mechanism of action (MoA) is based on disruption of bacterial cell membranes and is therefore effective regardless of bacterial genotype or resistance phenotype, and unlike conventional bacteriostatic antibiotics, it is fast acting and bactericidal. OMN6 has been optimized from the original AMP by Omnix Medical´s proprietary technology to exhibit not only remarkable efficacy, potency, and safety, but also high stability while maintaining bioactivity. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with Acinetobacter Infections.

RG6006: Roche

Zosurabalpin (RG6006) is a small molecule, novel chemical class antibiotic for the treatment of Acinetobacter baumannii infections. The drug is currently being evaluated under Phase I clinical trial for the treatment of patients with Obstructive sleep apnea.

Research programme: PBP inhibitor program: VenatoRx Pharmaceuticals

VenatoRx Pharmaceuticals is developing a novel class of non-beta-lactam molecules that kill bacteria by the same selective mechanism as beta-lactams - blocking cell wall synthesis via binding to the bacterial penicillin binding proteins (PBPs). Chemically distinct from the beta-lactams, these new molecules have been designed to be impervious to degradation by any beta-lactamases. The drug is currently in the Preclinical stage of development for the treatment of patients with Acinetobacter Infections.

Acinetobacter Infections: Therapeutic Assessment

This segment of the report provides insights about the different Acinetobacter Infections drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acinetobacter Infections

There are approx. 7+ key companies which are developing the therapies for Acinetobacter Infections. The companies which have their Acinetobacter Infections drug candidates in the most advanced stage, i.e. Phase II include, Omnix Medical.

Phases

The report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acinetobacter Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acinetobacter Infections: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Acinetobacter Infections therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acinetobacter Infections drugs.

Acinetobacter Infections Report Insights

• Acinetobacter Infections Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acinetobacter Infections Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acinetobacter Infections drugs?
• How many Acinetobacter Infections drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acinetobacter Infections?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acinetobacter Infections therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acinetobacter Infections and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Omnix Medical
• Roche
• Telum Therapeutics
• Spero Therapeutics
• VenatoRx Pharmaceuticals
• ABAC Therapeutics

Key Products

• OMN6
• RG6006
• Research programme
• SPR-206
• Research programme: PBP inhibitor program
• Research programme

This product will be delivered within 2 business days.